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significantly increase breast cancer 
risk. (2) There are many deleterious 
mutations, and each mutation is indi-
vidually rare. That is, for none of these 
genes (individually or in combination) 
does increased risk of breast cancer 
result from additive effects of mul-
tiple common alleles, each of small 
influence. Inherited breast cancer 
is highly genetically heterogeneous 
with respect to both loci and alleles 
involved. All evidence to date is that 
the model that best reflects this het-
erogeneity is not a “common disease-
common allele” model, but instead 
a “common disease-multiple rare 
alleles” model.
The ten known genes for inherited 
breast cancer function in a pathway 
whose role is to preserve genomic 
integrity. Roughly 50% of familial 
breast cancer remains unresolved 
by any of these genes. Clearly other 
genes in this pathway are worthy of 
in-depth genomic analysis in unre-
solved families. Furthermore, in thus 
far unrecognized members of this 
pathway, mutations may also be asso-
ciated with inherited breast cancer.
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The study of the genetics of Wilms tumor has led to several highly unexpected and precedent-estab-
lishing discoveries. Ironically, however, the identification of “WT genes” has been painfully slow, and 
gene mutations have been identified in only ?25% of tumors. The discovery of an X chromosome 
gene, WTX, that is mutated somatically in ?30% of Wilms tumors is notable both for helping to 
explain the genetic etiology of a substantial proportion of tumors and also for underscoring the role 
that X chromosome genes can play in cancer genetics.Wilms tumor (WT) is a childhood 
embryonal cancer of the kidney. Unlike 
most tumors, Wilms tumors gener-
ally exhibit few, if any, chromosomal abnormalities, and therefore WT was 
originally thought to represent a sim-
ple model for studying the genetic 
etiology of cancer. WT genetics, how-Cancer Cell 11ever, has turned out to be anything 
but simple; the road to identifying and 
understanding “WT genes” has been 
littered with false leads and dashed , February 2007 ©2007 Elsevier Inc. 105
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unexpected and precedent-establish-
ing discoveries. The recent report by 
Rivera et al. (2007) of the mutation of 
the novel X chromosome gene, WTX, 
in ?30% of Wilms tumor adds a sig-
nificant milestone to this road—and 
has provided yet another unexpected 
twist to the ever-evolving story.
Mathematical modeling of the age 
of onset and the frequency of bilat-
eral tumors in both familial and spo-
radic WT patients suggested that two 
genetic “hits” are critical, rate-limiting 
steps in tumor development (Knudson 
and Strong, 1972). Subsequently, a 
WT gene, WT1, was localized to chro-
mosomal band 11p13, and assess-
ment of DNA polymorphisms in tumor 
and matched normal tissue from 
patients demonstrated that ?40% of 
tumors displayed loss of heterozygos-
ity (LOH) at 11p loci. These data were 
consistent with a tumor suppressor 
gene model in which inactivation of 
both copies of the gene was required 
for tumorigenesis. Gene inactivation 
often occurred by mutation of one 
allele followed by loss of the remaining 
wild-type allele by chromosome dele-
tion, chromosome loss/reduplication, 
or somatic recombination. Once the 
WT1 gene was cloned, this model was 
confirmed at the molecular level.
But things weren’t so simple. Even 
before WT1 was isolated, unexpected 
data with—at the time—heretical impli-
cations began accruing. First was the 
observation that, in those tumors dis-
playing 11p LOH, it was invariably the 
11p alleles inherited from the father 
that were retained in the tumor (Schro-
eder et al., 1987). With the subsequent 
identification of a cluster of syntenic 
imprinted genes at 11p15 (telomeric 
of the WT1 locus), this novel observa-
tion in Wilms tumors brought the issue 
of gene imprinting out of the arena of 
mouse development and into the arena 
of human disease and cancer genet-
ics. It is now thought that the retention 
of paternal alleles in tumors is likely 
due to selection for the expression of 
the fetal mitogen, IGF2, that is located 
in the 11p15 imprinted region and is 
expressed during embryonic develop-
ment only from the paternally derived 
allele. In addition to those tumors dis-106 Cancer Cell 11, February 2007 ©200playing LOH, ?70% of Wilms tumors 
lose the normal 11p15 imprint and 
express both copies of the IGF2 gene 
(Ogawa et al., 1993; Rainier et al., 1993). 
This loss of imprinting (LOI) in WT was 
another “first” in cancer genetics and 
added to the complexity of molecular 
alterations that occur in WT.
Another startling finding came from 
studies of several large WT families. 
Familial predisposition to WT was not 
genetically linked to the WT1 region. 
These data implied that familial pre-
disposition was due to mutation of 
another, unknown gene and that WT 
was a genetically heterogeneous 
disease. This notion was reinforced 
once WT1 was cloned and mutational 
analyses were carried out on pan-
els of tumors. In one large study in 
which the entire WT1 coding region 
was assessed for both point muta-
tions and intragenic deletions, only 
18% of Wilms tumors carried a WT1 
mutation (Huff, 1998). Additionally, in 
tumors with wild-type WT1 the gene 
was almost invariably expressed, 
and WT1 transcripts were normally 
spliced and of wild-type sequence. 
Clearly there was another “WT” 
gene(s) whose alteration was critical 
for tumor development in those non-
WT1-mutated tumors. But where was 
it and what was it?
Progress in gene identification was 
slow. Identification of genes aberrantly 
expressed or silenced in tumors was 
difficult due to the fact that tumors, 
which are thought to arise from undif-
ferentiated renal mesenchyme, can 
be very histologically variable and are 
composed of cells that are reminis-
cent of the differentiated cell types 
that normally develop from renal 
mesenchyme. Were alterations in 
expression of a given gene etiologi-
cally important or simply a reflection 
of variable tumor histology?
p53 mutations were identified in 
?5% of Wilms tumors, but only in 
those with an anaplastic histology 
(Bardeesy et al., 1994). β-catenin 
mutations were identified in ?15% 
of tumors (Koesters et al., 1999), 
but these mutations were highly sig-
nificantly associated with WT1 muta-
tions (Maiti et al., 2000) and so would 
not be responsible for the genetic 7 Elsevier Inc.etiology of non-WT1 mutant tumors. 
Extensive cytogenetic, LOH, CGH, 
and genetic linkage studies revealed 
several regions of the genome 
thought to harbor a WT gene. How-
ever, until now, these studies have not 
resulted in the clear identification of a 
WT gene. Thus, the report of a gene 
(WTX) that is mutated in almost 30% 
of a series of 51 Wilms tumors is a 
major breakthrough.
However, as is usual with any such 
discovery, a multitude of questions 
arise. Why haven’t deletions of the X 
chromosome been observed before? 
The answer is, deletion of the entire 
X chromosome was noted occa-
sionally, but intrachromosomal dele-
tions were not. Presumably only with 
higher-resolution arrays utilizing long 
oligonucleotides could the relatively 
small (?1 Mb or less) interstitial X 
chromosome deletions reported by 
Rivera et al. (2007) be detected. And, 
luckily, the commonly deleted region 
mapped within a single gene. Even 
more fortunately, WTX sequence 
variants observed in tumors were 
somatic, and almost all were truncat-
ing mutations and so were likely of 
functional significance.
What does WTX do? The sequence 
of the predicted encoded protein pro-
vides few clues. Although primate, 
mouse, rat, dog, and cow orthologs 
have been identified or predicted, 
WTX shares no significant homology 
with genes of known function. Ectopic 
expression of WTX in two cell lines 
resulted in a reduction in colony for-
mation and an increase in apoptosis 
in one line. However, these were not 
WT cell lines, nor were the observed 
WTX truncation mutations tested in 
these assays, so these observations 
may or may not relate to the actual 
function of WTX.
WTX mutations and WT1 mutations 
were mutually exclusive, suggest-
ing that WT1 and WTX may function 
in the same cellular pathway. Does 
WT1, a known transcription factor, 
regulate WTX? WTX, unlike WT1, was 
expressed more robustly in neonatal 
and adult lung than in neonatal and 
adult kidney. However, in kidney the 
expression pattern for the two genes 
was similar. Although this similar pat-
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being expressed in the same precur-
sor and adult cell types, the pres-
ence of two putative WT1 binding 
sites in the promoter region of WTX 
(E.C. Ruteshouser, personal commu-
nication) hints that WT1 may regulate 
WTX, at least in kidney. If this is the 
case, mutation of either gene could 
serve to abrogate the function of the 
same pathway critical for normal kid-
ney development.
Do WTX mutant tumors represent a 
distinct subset of tumors with respect 
to tumor histology, presence of pre-
neoplastic lesions, age of onset, fam-
ily history, disease progression, prog-
nosis, etc? This is currently unknown, 
but this type of data may help provide 
clues to the function of WTX. The 
WTX mutations observed to date are 
somatic mutations and therefore can-
not account for the familial predispo-
sition to WT. Additionally, in most WT 
families predisposition is not inherited 
as an X-linked disease. Do tumors 
from familial cases, however, sustain 
somatic WTX mutations, suggestive 
of the importance of mutating at least 
two distinct loci? Does the fact that a 
single alteration can inactivate a gene 
residing on the X chromosome fac-tor into the relatively high (for Wilms 
tumors) frequency of tumors with WTX 
mutations?
Interestingly, the frequency of WTX 
mutations in tumors from male and 
female WT patients is the same. This 
is unexpected, since a WTX somatic 
mutation, if randomly occurring on 
both the active and inactive X chro-
mosomes, would always mutate the 
functional gene in males, but would 
mutate the functional gene on the 
active X chromosome only half the 
time in females. Along the same lines, 
one would also expect that the Wilms 
patient population would be skewed 
toward males, but this is not the case. 
In fact, in North America, there is a 
small, but statistically significant pre-
dominance of females (Breslow et al., 
1988). Is the lack of male predomi-
nance for a disease that often (30% of 
the time) involves an X chromosome 
gene mutation telling us something 
about the mutability of the WTX gene 
on the active versus the inactive X 
chromosome?
So yet again, a discovery in the 
field of WT genetics is at once excit-
ing, unexpected, novel, and puzzling. 
For such a simple model, WT keeps 
challenging us.Cancer Cell 1RefeRences
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